Advaccine is based in Suzhou, China. It has raised $166M in total funding. Latest round: IPO.
Advaccine funding overview
Advaccine is based in Suzhou, China. Advaccine has raised $166M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is an IPO announced in February 2023. The round record for Advaccine runs through 2023; nothing later has been disclosed. Investors on record include Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group. 5 distinct backers are named across the disclosed rounds.
Advaccine at a glance
Total raised
$166M
Latest round
IPO
Latest round date
February 2023
Headquarters
Suzhou, China
Notable investors
Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group
Frequently asked about Advaccine funding
How much has Advaccine raised?
Advaccine has raised $166M in total disclosed funding across the rounds on record.
Who has invested in Advaccine?
Goldstream Investment, Hony Capital, Wosheng Investment, Dunhong Capital Management, Red Horse Investment Group are named among the investors backing Advaccine.
What was the latest Advaccine funding round?
The most recent disclosed round is an IPO, announced in February 2023.
Where is Advaccine based?
Advaccine is based in Suzhou, China.
When did Advaccine last raise?
The last disclosed Advaccine round closed in February 2023 at IPO.
Totals shown for Advaccine aggregate every disclosed round on file. To see how that compares, browse the companies in Suzhou and the investors behind them below.
